4 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow CaCP29: new trials by email Literature Review of CaCP29 trials Research Report on CaCP29
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum vilobelimab - Pyoderma Gangrenosum | Phase 2 | Completed | InflaRx GmbH | 19 | 2019-05-16 | 2023-09-14 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Terminated | InflaRx GmbH | 20 | 2018-10-15 | 2022-05-26 |
| Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) IFX-1, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Completed | InflaRx GmbH | 179 | 2018-02-26 | 2021-04-08 |
| Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction CaCP29, Placebo - Severe Sepsis, Septic Shock | Phase 2 | Completed | InflaRx GmbH | 72 | 2014-04-01 | 2016-04-25 |
Granulomatosis with Polyangiitis (2) · Microscopic Polyangiitis (2) · Hidradenitis Suppurativa (1) · Inflammation (1) · Pyoderma Gangrenosum (1) · Sepsis (1) · Shock, Septic (1) · Skin Diseases (1) · Systemic Inflammatory Response Syndrome (1) · Systemic Vasculitis (1)
InflaRx GmbH (5)
Canada (3) · Germany (3) · United States (3) · France (2) · Netherlands (2) · Poland (2) · Belgium (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Greece (1) · Italy (1) · Russia (1) · Spain (1) · Sweden (1)
Peter A. Merkel, MD, MPH (2) · Anja Pfaff, PhD (1) · Korinna Pilz, MD, MS (1) · Michael Bauer, Prof. Dr. (1) · Othmar Zenker, CMO (1) · Prof. Niels C. Riedemann, M.D., Ph.D. (1)